Tag Archives: NIH

FDA Gets More Funding, IPAB Gets Less

After two years in budget limbo, Congress finally enacted federal spending legislation for fiscal year 2014 last week, just before the latest funding extension ran out. In this period of ever-tighter government outlays, the Food and Drug Administration did fairly well in gaining additional funds, along with user fee revenues that had been put on […]
Posted in FDA, healthcare, Legal, Regulatory, Safety | Also tagged , , , , , , , | Leave a comment

Kineta: Creative Financing Bridges the "Valley of Death"

At a time when burst bubbles have created uncertainty for investors in the biomedical realm, it’s smart for a drug company to make use of new legislation and emerging trends in venture capital. This is particularly true in spurring confidence in that translational area of drug development many deem the “Valley of Death”. PharmExec caught […]
Posted in Biotech, Deals, leadership, R&D, Regulatory, Strategy | Also tagged , , , , , , , , , , , , , , | Leave a comment

Woodcock Urges Forward March Toward Personalized Medicine

New approaches for conducting clinical trials and developing therapies that actually prevent and cure disease are key to the future of effective drug therapy, according to Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research (CDER). Personalized medicine has achieved mainstream status, accounting for more new drug approvals and promising pipeline candidates, […]
Posted in Technology | Also tagged , , , , , , , , , , | Leave a comment

Budget Cutters Propose Big Hits on Pharma

By Jill Wechsler, Washington Correspondent. The Obama administration’s budget plan for fiscal year 2014 apparently assumes that the pharmaceutical industry can support Medicare and other health programs through changes in drug coverage and payments. It also relies on industry fees to keep the Food and Drug Administration up and running. Meanwhile, FDA and other public […]
Posted in Guest Blog, healthcare, Op-Ed | Also tagged , , , , , , | Leave a comment

Sequestration: How Big a Hit for FDA, Research and Pharma?

The greatly feared federal budget sequestration mandate went into effect March 1, and, initially, the impact was fairly muted. The stock market soared, employment rose and government workers continued on their jobs. Federal agencies, including the Food and Drug Administration (FDA), launched initiatives to comply with the mandated 5% across-the-board cut in spending (in reality […]
Posted in FDA, healthcare, leadership, Legal, R&D | Also tagged , , , , , , | Leave a comment
  • Categories

  • Meta